Amnolake (tamibarotene) / Syros 
Welcome,         Profile    Billing    Logout  
 33 Diseases   7 Trials   7 Trials   272 News 


123»
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Abundance of Relapse-Predictive Cells Can be Estimated at Diagnosis and Is Strongly Associated with Outcome in Pediatric AML (Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)) -  Nov 6, 2024 - Abstract #ASH2024ASH_1322;    
    Patient-derived xenograft (PDX) models were treated with cytarabine (50 mg/kg/dose) or saline on days 1-4...The RARA/RXRA complex represses transcription in the absence of retinoic acid; transcription can be activated by the agonist tamibarotene (tami)...We validated the association of these cell types with chemoresistance in PDX models. We identified retinoic acid receptor agonism as a potential strategy to deplete one of these cell types.
  • ||||||||||  Translarna (ataluren) / PTC Therap, Amnolake (tamibarotene) / Syros
    Journal:  Photoinduced Cu(II)-Mediated Decarboxylative Thianthrenation of Aryl and Heteroaryl Carboxylic Acids. (Pubmed Central) -  Jul 16, 2024   
    Mechanistic studies are in line with a reaction occurring through a photoinduced ligand-to-metal charge transfer (LMCT) of Cu(II)-arylcarboxylates, enabling radical decarboxylative carbometallation to form arylcopper(II) intermediates that in turn react with thianthrene to form the product. Noteworthy, the susceptibility of aryl thianthrenium salts to photodegradation is overcome by a Cu(I)-driven salvage loop, which continuously intercepts the transiently formed radicals and regenerates the products.
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Biomarker, Journal:  Identification of shared disease marker genes and underlying mechanisms between rheumatoid arthritis and Crohn disease through bioinformatics analysis. (Pubmed Central) -  Jun 28, 2024   
    Finally, tamibarotene, retinoic acid, and benzo[a]pyrene were identified as potential treatment options for patients with both RA and CD...Interestingly, the study has highlighted hsa-miR-31-5p as a potential key player in the common mechanism of both diseases, representing a new direction in research and a potential therapeutic target. These shared genes, potential mechanisms, and regulatory networks offer new opportunities for further research and may provide hope for future treatment of patients with both RA and CD.
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Review, Journal:  How Do Retinoids Affect Alzheimer's Disease and Can They Be Novel Drug Candidates? (Pubmed Central) -  Apr 4, 2024   
    This means that when administering these agents, their actions are to target a single disease-causing pathway at a time but do not affect other pathways. On the other hand, tamibarotene is a novel drug candidate that targets a range of pathways at once and provides a more comprehensive approach in its pharmacological actions.
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Trial completion date, Trial primary completion date, Combination therapy:  SELECT-AML-1: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML (clinicaltrials.gov) -  Feb 22, 2024   
    P2,  N=95, Recruiting, 
    This is considered a valuable case for accumulating information on the treatment of CD56-positive APL resistant to ATRA and ATO. Trial completion date: Apr 2024 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2028
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Journal:  Blood transcriptome analysis uncovered COVID-19-myocarditis crosstalk. (Pubmed Central) -  Feb 20, 2024   
    TBKBP1 and ERGIC1 were identified as crucial genes in the development of COVID-19-related myocarditis and have demonstrated a strong association with innate antiviral immunity. The present work may be helpful for further investigation of the molecular mechanisms and new therapeutic drug targets correlated with myocarditis in COVID-19.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, Amnolake (tamibarotene) / Syros
    Review, Journal:  Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects. (Pubmed Central) -  Feb 10, 2024   
    To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.
  • ||||||||||  Nypta (tideglusib) / ASD Therap, Amnolake (tamibarotene) / Syros
    Journal:  Cocktail Cell-Reprogrammed Hydrogel Microspheres Achieving Scarless Hair Follicle Regeneration. (Pubmed Central) -  Jan 16, 2024   
    In vitro and in vivo studies show that AHFS can regulate fibroblast fate, induce fibroblast-to-DPC reprogramming by activating the PI3K/AKT pathway, finally promoting wound healing and in situ HF regeneration while inhibiting scar formation in a two-pronged translational approach. In conclusion, AHFS provides a new and effective strategy for functional repair of skin wounds.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Amnolake (tamibarotene) / Syros
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Combination therapy:  Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia (clinicaltrials.gov) -  Oct 25, 2023   
    P1/2,  N=0, Withdrawn, 
    In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 Not yet recruiting --> Withdrawn | N=52 --> 0 | Trial completion date: Jan 2030 --> Oct 2023 | Initiation date: Mar 2024 --> Sep 2023 | Trial primary completion date: Jan 2028 --> Oct 2023
  • ||||||||||  peretinoin (K-333) / Kowa, Bay11-7082 / Bayer, Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
    Preclinical, Journal:  Acyclic retinoid peretinoin reduces hemorrhage-associated brain injury in vitro and in vivo. (Pubmed Central) -  Oct 22, 2023   
    Not yet recruiting --> Withdrawn | N=52 --> 0 | Trial completion date: Jan 2030 --> Oct 2023 | Initiation date: Mar 2024 --> Sep 2023 | Trial primary completion date: Jan 2028 --> Oct 2023 On the other hand, nuclear factor-?B (NF-?B) inhibitors such as pyrrolidine dithiocarbamate (50
  • ||||||||||  An Update on Higher Risk Myelodysplastic Syndromes () -  Aug 31, 2023 - Abstract #SOHO2023SOHO_939;    
    Therapies The current treatment landscape for HR-MDS is limited to HMA monotherapy, either parenteral (azacitidine or decitabine) or a more recently available oral option (decitabine/cedazuridine), followed by allogeneic hematopoietic stem cell transplant when feasible based on patient fitness and donor availability.14,15 There is a great need for alternative agents in the front-line and HMA-failure settings, as outcomes are particularly dismal in the latter.16,17 Unfortunately, drug development in MDS has been hampered by poorly-understood disease biology, lack of quality animal models, broad heterogeneity in disease phenotype, and suboptimal patient accrual to trials.18,19 Therapies more recently approved in AML are now being evaluated in HR-MDS. Liposomal daunorubicin/cytarabine (CPX-351) in the front-line setting has some promising, albeit limited, data published so far.20
  • ||||||||||  Vesanoid (tretinoin) / Roche, Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
    Review, Journal:  The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away. (Pubmed Central) -  Jul 29, 2023   
    through strong SE levels in the gene locus and increased sensitivity to tamibarotene. Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials.
  • ||||||||||  Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
    Journal:  Tamibarotene targets heparin-binding protein for attenuating lung injury in sepsis. (Pubmed Central) -  Jul 13, 2023   
    Combined with a hypomethylating agent, synthetic retinoids have shown synergistic anti-leukemic effects in non-APL AML preclinical models and are now being studied in phase II and III clinical trials. These findings demonstrated that tamibarotene lessens sepsis-induced lung injury, and the effect could be exerted by targeting HBP and thereby deregulating the NF-?B signaling pathway.
  • ||||||||||  Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
    Journal:  Integrated Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unravels the Influences of SARS-CoV-2 Infections to Cancer Patients. (Pubmed Central) -  Dec 24, 2022   
    The candidate drug molecules (e.g., Tamibarotene CTD 00002527) obtained by this study might be helpful for effective therapeutic targets in COVID-19 patients with cancer...Specifically, changes in the expression level of TNFSF10 in monocytes can be considered as an immune signature in COVID-19 patients with hematologic cancer. Targeting N-methyladenosine (m6A) pathways (e.g., METTL3/SERPINA1 axis) to restrict SARS-CoV-2 reproduction has therapeutic potential for COVID-19 patients.
  • ||||||||||  Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia
    Journal:  Identification of significant modules and hub genes involved in hepatic encephalopathy using WGCNA. (Pubmed Central) -  Nov 25, 2022   
    Our study not only promoted the current understanding of neuroinflammation in HE, but also provided the first evidence that CYBB and FOXO1 played pivotal roles in the pathogenesis of HE, which might be potential biomarkers and therapeutic targets. Tamibarotene might be a novel drug compound against HE.
  • ||||||||||  Amnolake (tamibarotene) / Syros
    Trial completion date, Trial primary completion date, Combination therapy:  SELECT-AML-1: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML (clinicaltrials.gov) -  Nov 14, 2022   
    P2,  N=95, Recruiting, 
    Tamibarotene might be a novel drug compound against HE. Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Apr 2024